Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
I'm PortAI, I can summarize articles.
Gedatolisib triplet cut the risk of disease progression or death by 76% vs. fulvestrant. Median progression-free survival improved to 9.3 months with the triplet vs. 2.0 months with fulvestrant. The market's back, and these 3 income stocks are thriving. See them here→ Celcuity Inc.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments